The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma

BACKGROUND: Treatment with PARP inhibitors (PARPi) is primarily effective against high-grade serous ovarian cancers (HGSOC) with BRCA1/2 mutations or other deficiencies in homologous recombination (HR) repair mechanisms. However, resistance to PARPi frequently develops, mostly as a result of BRCA1/2...

Descripción completa

Detalles Bibliográficos
Autores principales: Morra, Francesco, Merolla, Francesco, Damia, Giovanna, Ricci, Francesca, Varricchio, Silvia, Ilardi, Gennaro, Arenare, Laura, Califano, Daniela, Napolitano, Virginia, Fruscio, Robert, Melillo, Rosa Marina, Palazzo, Luca, Celetti, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375931/
https://www.ncbi.nlm.nih.gov/pubmed/35964058
http://dx.doi.org/10.1186/s13046-022-02459-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375931/
https://www.ncbi.nlm.nih.gov/pubmed/35964058
http://dx.doi.org/10.1186/s13046-022-02459-2

Ejemplares similares